Helicobacter pylori (H. pylori ) Infection is caused by bacteria, which in turn, causes stomach infection. This Infection thus causes changes to the stomach and duodenum that leads to gastritis and stomach cancer. The consumption of contaminated food and water (with faecal matter) spreads H. pylori infection.
The bacteria infects the protective tissue that lines the stomach, which leads to the release of certain enzymes and toxins and activates the immune system. Together, these factors may directly or indirectly injure the cells of the stomach or duodenum, which leads to chronic inflammation in the walls of the stomach (gastritis) or duodenum (duodenitis).
In the United States and other developed countries, Infection with H. pylori is unusual during childhood but becomes more common during adulthood. However, sometimes children may get infected before the age of 10 years.
H. pylori cause chronic gastritis and have been associated with several serious diseases of the gastrointestinal tract, including duodenal ulcer and gastric cancer.
At least half of the world's population is infected by Helicobacter Pylori, and most of the infected people (>70%) are asymptomatic, whereas <30% are symptomatic
As per the study conducted by Sitas et al., it estimates that the overall prevalence of H. pylori was 56.9%, increasing sharply in middle age from 29.8% in those aged 30–34 to over 59% in those aged 45 or older
According to Everhart et al., the prevalence of H. pylori is higher in Hispanics, African Americans, and the elderly. Its prevalence is 60% in Hispanics, 54% in African Americans, and 20% in Whites
Key players in the Helicobacter Pylori (H. pylori) Market includes such as Redhill Biopharma, Phatom Pharma, CJ HealthCare, AzurRx BioPharma, and many others are involved in developing therapies for Helicobacter pylori infection.
Expected launch of emerging therapies in Helicobacter Pylori (H. pylori) Market, such as Vonoprazan (Phatom Pharma), K-Cab (CJ HealthCare), MTAN Inhibitors (AzurRx BioPharma), and others are expected to impact the market size of Helicobacter pylori Infection in the upcoming years.
For more details visit: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market
#Helicobacter #Pylori #HelicobacterPylori #hpylori #pharmaceutical #biotechnology #lifescience #healthcare